Download PDF

1. Company Snapshot

1.a. Company Description

IP Group Plc is a private equity and venture capital firm specializing in seed, early stage, start-up, incubation, growth capital, and mature financing.The firm also provides seed capital financing to spin out companies from the universities.It seeks to invest in the life sciences, physical sciences, energy & renewables, medical equipment and supplies, healthcare, technology, cleantech, intellectual property, pharmaceuticals & biotechnology, information technology & communications, and chemicals & materials.


It also provides support for its university partners' intellectual property commercialization activities, as well as in the identification of intellectual property.It typically invests between £0.5 million ($0.75 million) and £1 million ($1.50 million) per investment.The firm prefers to takes equity positions in its portfolio companies.


IP Group Plc was founded in 2001 and is based in London, United Kingdom with additional offices in Wilmington, Delaware; London, United Kingdom; Oxford, United Kingdom; Hong Kong S.A.R., Hong Kong and Melbourne, Australia.

Show Full description

1.b. Last Insights on IPO

IP Group Plc's recent performance was buoyed by a narrowed net loss of UK£43.0m in the first half of 2025, a 61% improvement from the same period last year. Earnings per share also showed a positive trend, with a reduced loss of UK£0.045 per share, compared to UK£0.11 in 1H 2024. According to recent reports, the company's strategic focus on innovation and growth has yielded promising results. A recent rating upgrade by Shore Capital, citing the company's robust portfolio and improving financials, further underscores the positive momentum.

1.c. Company Highlights

2. IP Group Plc's H1 2025 Earnings Report: A Strong Performance

The company's financial performance in H1 2025 was robust, driven by significant milestones in its portfolio. The actual EPS came in at 0.999, far exceeding estimates of 0.016. Revenue growth is anticipated to be 1313.3% next year, according to analysts' estimates. The NAV per share stabilized at GBP1, supported by strong public market performance, including Hinge Health’s IPO and Oxford Nanopore’s trading.

Publication Date: Sep -20

📋 Highlights
  • Cash Proceeds from Exits:: GBP 30 million generated in H1 2025, 9x higher than H1 2024, with GBP 237 million gross cash toward GBP 250 million 2027 target.
  • Hinge Health IPO Gain:: GBP 30 million net gain from IPO, with stock up 80% post-listing, contributing to total realizations.
  • Oxford Nanopore Performance:: Portfolio top holding outperformed, with GBP 105 million revenue (28% YoY growth) and IP Group as second-largest shareholder.
  • Share Buybacks:: GBP 75 million program accelerated, with GBP 9 million remaining, retiring 15% of shares to reduce discount to NAV.
  • Strategic Portfolio Focus:: 50% of investments in UK science/tech, leveraging policy shifts (e.g., Mansion House Accord) and university partnerships for long-term value.

Financial Highlights

The company reported GBP30 million in cash proceeds from exits in H1 2025, a significant increase from H1 2024. The gross cash balance stood at GBP237 million, reflecting a 47% YoY growth. The loss for the period was GBP43 million, which was offset by post-period gains in Nanopore and Hinge Health. The company's cash flow included GBP35 million invested, GBP30 million realized, and GBP25 million in share buybacks.

Valuation Metrics

To understand what's priced into IP Group Plc's stock, we can look at its valuation metrics. The 'P/E Ratio' is -2.56, 'P/B Ratio' is 0.55, and 'P/S Ratio' is -14.87. The 'EV/EBITDA' is -1.77, 'Dividend Yield (%)' is 0.0, and 'Free Cash Flow Yield (%)' is -5.54. The 'ROE (%)' is -20.25, indicating a challenging period for the company's profitability. These metrics suggest that the market is pricing in significant growth potential, particularly in the company's ability to generate exits and realize value from its portfolio.

Portfolio Updates

Hinge Health, a portfolio company, achieved a successful IPO, with its stock rising 80% post-IPO. Oxford Nanopore, another key holding, reported a 28% revenue rise to GBP105 million, driven by expansion across clinical and applied markets. Other portfolio companies, such as Istesso and Centessa, are making progress in their respective clinical trials and research initiatives.

Strategic Initiatives

The company is focused on scaling its UK innovation platform, leveraging policy shifts like the Mansion House Accord. It is also pursuing new private capital mandates to support its growth ambitions. The company's strategic priorities include disciplined capital allocation, portfolio liquidity, and long-term value creation through its science-backed investments. As Greg Smith noted, the company is positioning itself for market opportunities, with a strong NAV per share and disciplined buybacks to close share price discounts.

3. NewsRoom

Card image cap

IP Group First Half 2025 Earnings: UK£0.045 loss per share (vs UK£0.11 loss in 1H 2024)

Sep -19

Source:

Card image cap

Stocks to watch next week: Tesla, Alphabet, Intel, Lloyds and JD Wetherspoon

Jul -18

Source:

Card image cap

Every fusion startup that has raised over $100M

Jun -19

Source:

Card image cap

British nuclear fusion pioneer wipes millions off its value after quitting reactor plans

Apr -27

Source:

Card image cap

British nuclear fusion pioneer plunges after ditching reactor plans

Apr -27

Source:

Card image cap

IP Group PLC (STU:IOOA) (Q4 2024) Earnings Call Highlights: Strategic Exits and Share Buybacks ...

Mar -26

Source:

Card image cap

Visa finalises purchase of paytech Featurespace

Dec -20

Source:

Card image cap

IP Group PLC (IPZYF) (Q2 2024) Earnings Call Transcript Highlights: Strong Cash Realizations ...

Sep -18

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.53%)

6. Segments

Life Sciences

Expected Growth: 10.47%

Strong demand for innovative healthcare solutions, increasing investment in R&D, and strategic partnerships drive growth in Life Sciences at IP Group Plc. The segment benefits from a robust pipeline of novel therapeutics, diagnostics, and medical devices, as well as a growing need for personalized medicine and gene editing technologies.

Other

Expected Growth: 10.27%

IP Group Plc's 10.27% growth is driven by its diversified portfolio of intellectual property-based businesses, strong partnerships, and strategic investments in high-growth sectors such as cleantech, healthcare, and technology. Additionally, the company's focus on innovation, R&D, and commercialization of new technologies contributes to its growth momentum.

Oxford Nanopore

Expected Growth: 11.27%

Oxford Nanopore's 11.27% growth is driven by increasing adoption of its portable, real-time DNA sequencing technology in research and clinical settings, coupled with expanding partnerships and collaborations, particularly in the Asia-Pacific region. Additionally, growing demand for precision medicine and genomic analysis, as well as strategic investments from IP Group Plc, contribute to the company's rapid growth.

Regenerative Future

Expected Growth: 10.27%

Regenerative Future from IP Group Plc's 10.27% growth is driven by increasing demand for sustainable solutions, government incentives for eco-friendly technologies, and strategic investments in research and development. Additionally, the growing awareness of environmental issues and the need for renewable energy sources are contributing to the segment's rapid expansion.

Tech-enriched Future

Expected Growth: 9.9%

IP Group Plc's 9.9% growth in Tech-enriched Future is driven by increasing demand for digital transformation, rising adoption of AI and IoT, and growing need for cybersecurity. Additionally, investments in 5G and cloud infrastructure, as well as the proliferation of smart devices, are fueling growth in this segment.

Third Party Fund Management

Expected Growth: 9.9%

IP Group Plc's 9.9% growth in Third Party Fund Management is driven by increasing demand for diversified investment portfolios, expansion into new markets, and strategic partnerships. Additionally, the company's expertise in intellectual property commercialization and strong relationships with universities and research institutions contribute to its growth.

7. Detailed Products

University IP Commercialisation

IP Group partners with top universities to commercialise their intellectual property, providing funding, expertise and networks to turn innovative ideas into successful businesses.

Spin-out Company Formation

IP Group forms spin-out companies based on university intellectual property, providing funding, management and expertise to turn innovative ideas into successful businesses.

IP Portfolio Management

IP Group manages a portfolio of intellectual property, providing strategic guidance and expertise to maximise the value of IP assets.

Licensing and Partnerships

IP Group licenses intellectual property to industry partners, providing access to innovative technologies and expertise.

Funding and Investment

IP Group provides funding and investment to support the development of innovative ideas and companies.

8. IP Group Plc's Porter Forces

Forces Ranking

Threat Of Substitutes

IP Group Plc's patent portfolio and intellectual property rights provide a moderate barrier to entry for substitutes, but the increasing trend of open innovation and collaborative R&D may reduce the switching costs for customers.

Bargaining Power Of Customers

IP Group Plc's customers, primarily universities and research institutions, have limited bargaining power due to the specialized nature of IP Group's services and the lack of alternative providers.

Bargaining Power Of Suppliers

IP Group Plc has a diverse supplier base, and the company's specialized services reduce the bargaining power of suppliers, making it difficult for them to negotiate better prices or terms.

Threat Of New Entrants

The threat of new entrants is high due to the increasing trend of open innovation and collaborative R&D, which reduces the barriers to entry for new players in the intellectual property management and commercialization industry.

Intensity Of Rivalry

The intensity of rivalry in the intellectual property management and commercialization industry is moderate, with a few established players competing for market share, but IP Group Plc's strong brand reputation and diversified services help to mitigate the competitive pressure.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 11.54%
Debt Cost 3.95%
Equity Weight 88.46%
Equity Cost 10.78%
WACC 9.99%
Leverage 13.04%

11. Quality Control: IP Group Plc passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Bois Sauvage

A-Score: 5.6/10

Value: 7.9

Growth: 2.7

Quality: 4.3

Yield: 5.0

Momentum: 5.5

Volatility: 8.3

1-Year Total Return ->

View Full Report
Stock-Card
Brooks Macdonald

A-Score: 5.5/10

Value: 4.2

Growth: 2.7

Quality: 7.5

Yield: 7.5

Momentum: 5.0

Volatility: 6.0

1-Year Total Return ->

View Full Report
Stock-Card
IP Group

A-Score: 4.6/10

Value: 9.8

Growth: 0.6

Quality: 7.2

Yield: 1.2

Momentum: 5.5

Volatility: 3.3

1-Year Total Return ->

View Full Report
Stock-Card
MedCap

A-Score: 4.4/10

Value: 1.1

Growth: 9.0

Quality: 7.6

Yield: 0.0

Momentum: 7.0

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Bellevue

A-Score: 4.0/10

Value: 4.4

Growth: 2.4

Quality: 6.1

Yield: 9.4

Momentum: 0.0

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
BAVARIA

A-Score: 3.9/10

Value: 5.7

Growth: 3.0

Quality: 7.4

Yield: 0.0

Momentum: 4.0

Volatility: 3.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

0.62$

Current Price

0.62$

Potential

-0.00%

Expected Cash-Flows